GlassScriptPhysician profile
Todd H Lustig
NPI 1659342954
$1,904.11
in general payments reported to CMS, 2019-2025
25 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $136 · 2021: $252 · 2022: $222 · 2023: $336 · 2024: $368 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $329.55 | 2024-2025 | Vevye |
| Alcon Vision LLC | $158.24 | 2019-2025 | Precision7, Total30, Simbrinza |
| Johnson & Johnson Vision Care, INC. | $124.99 | 2023 | Acuvue |
| Bausch & Lomb Americas INC. | $106.96 | 2022-2025 | Vyzulta, Miebo, Lotemax Sm |
| Kala Pharmaceuticals, INC. | $102.54 | 2021 | |
| Biotissue Holdings INC. | $100.04 | 2022 | |
| Abbvie INC. | $99.59 | 2022-2025 | |
| Visioneering Technologies, INC. | $96.11 | 2019 | |
| Coopervision INC. | $95.56 | 2021-2023 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Asd Specialty Healthcare, LLC | $62.15 | 2020 | |
| Maculogix, INC. | $58.25 | 2019 | |
| Genzyme Corporation | $55.85 | 2020 | |
| Genentech USA, INC. | $54.37 | 2024-2025 | Vabysmo |
| Allergan, INC. | $50.16 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $49.35 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.73 | 2019-2021 | |
| Rxsight INC | $46.72 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Horizon Therapeutics Plc | $37.85 | 2023 | Tepezza |
| Dompe US, INC. | $32.43 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $31.17 | 2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $30.69 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $24.04 | 2022 | |
| Astellas Pharma US INC | $19.92 | 2025 | Izervay |
| Sight Sciences, INC. | $17.53 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Lustig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.